New avenues for treating metabolic dysfunction-associated fatty liver disease
Peer-Reviewed Publication
Updates every hour. Last Updated: 7-Sep-2025 21:11 ET (8-Sep-2025 01:11 GMT/UTC)
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions worldwide. This complex liver disorder ranges from simple steatosis to more severe forms, including metabolic dysfunction-associated steatohepatitis (MASH), which may progress to fibrosis, cirrhosis, and even liver cancer. The latest insights into transcription factors provide a deeper understanding of the disease’s progression and potential therapeutic interventions.